We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
OvuSense has been designed for women that struggle to conceive, actively predicting fertility patterns.  The OvuSense system has two parts a smartphone app and a medical grade vaginal sensor. OvuSense works for all women. The product gives a 24 hour prediction within your cycle.
days to go: Expired investment: £100,000
A technological healthcare service allowing patients to discuss any concerns with a GP, clinician or specialists via video consultations, home visits, or appointments at the clinic. DocNoc launched less than 12 months ago and has over 160 NHS and private sector doctors and clinics registered on the service. The company's business model is easily flexible and aim to launch DocNoc internationally.
days to go: Expired investment: £269,710
Using AI technology to help the elderly feel safer and more comfortable in their homes. miicare has developed wearable devices and wireless sensors to monitor body vitals. If any irregularity occurs a call will be placed to a family member, a social worker, or a 24/7 professional telecare service. This increases support for the elderly and peace of mind knowing an emergency can be easily and quickly addressed. All data is secured using blockchain encryption.
days to go: Expired investment: £321,920
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £388,038
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go: Expired investment: £433,290
Speeding up access to mental health treatments by using electronic forms and universal communication tools. Thalamos has created a solution for multiple health entities such as the NHS, social services, charities, etc. The company aims to move these entities away from pen and paper, to an easy-to-use online platform, as manual entries are prone to information and data being misplaced, as well as prone to errors. Thalamos's cloud platform will enable psychiatrists to reduce their clinical and information governance risk, whilst helping to continuously improve their patients' recovery process. The product will be subscription-based from £600 per year, which can be paid monthly and is in-line with other professional services.
days to go: Expired investment: £171,548
Qure’s aim is to provide individual healthcare that is both affordable and highly convenient, becoming the platform of choice for both patients and practitioners. Qure offer 24/7 private healthcare, without the huge price tag that is usually associated with these kinds of services. 
days to go: Expired investment: £1,162,206
Active Needle is a medical device company that aims to prevent the problem of needle placement errors in ultrasound-guided needle interventional procedures. The technology allows for precision needle targeting.
days to go: Expired investment: £147,514
Cardiovascular Disease is the leading cause of death in the UK, PlaqueTec have developed a Liquid Biopsy System, which allows cardiologists to gain further information from a patient's coronary artery and provide more effective treatment to those affected by the disease.
days to go: Expired investment: £1,493,593
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,036,436
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph